ENDV - Endonovo Therapeutics, Inc.

Other OTC - Other OTC Delayed price. Currency in USD
0.0148
0.0000 (0.00%)
At close: 12:44PM EDT
Stock chart is not supported by your current browser
Previous close0.0148
Open0.0149
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0148 - 0.0148
52-week range0.0010 - 0.0280
Volume43,784
Avg. volume226,031
Market cap4.168M
Beta (5Y monthly)0.50
PE ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings date04 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Endonovo Launches SofPulse® into the Veterans Administration

    Los Angeles, CA, May 02, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) a US-based biotechnology developer, today announced the launch of SofPulse® with Academy Medical, Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB) Government Reseller. As was previously announced, Academy Medical will be reselling SofPulse® medical devices to the Veterans Health Administration (VHA) healthcare facilities, thereby ensuring its availability to the country’s military, veterans

  • GlobeNewswire

    Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies

    Los Angeles, CA, April 25, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment. The Company is actively seeking to collaborate with several renowned clinical researchers and top global cognitive institutes for studies evaluating the effectiveness of SofPulse® in treating TBI patients. The studies will assess the effic

  • GlobeNewswire

    Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman

    Los Angeles, CA, April 13, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial stage developer of non-invasive medical devices, is pleased to announce its partnership with David Irving, former NFL (National Football League) defensive lineman, as brand ambassador for SofPulse®, a non-opioid pain and inflammation relief technology. Irving will share his experiences and results using SofPulse® for the management of his pain and inflammation. In studies, SofPulse® contin

  • GlobeNewswire

    Endonovo Announces Partnership with Santana Lead Singer Andy Vargas

    Los Angeles, CA, April 10, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc (OTCQB: ENDV) -- a pioneer in bioelectronic medical devices -- announced today its partnership with world-renowned musician and philanthropist, Andy Vargas, and his wife, Nicole Vargas, to promote its innovative non-opioid pain relief technology, SofPulse® PEMF (Pulsed Electro Magnetic Frequency) device. The partnership with Vargas will provide the Company with peer-to-peer and referral marketing reviews of SofPulse® a

  • GlobeNewswire

    Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company

    Los Angeles, CA, March 29, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) today announced a binding Letter of Intent (LOI) to spin off its current medical device division to an entity controlled by Ira Weisberg, who will be the future President and CEO of a newly formed publicly-traded Delaware company, tentatively named SofPulse, Inc. As a condition of the executed LOI and to establish fair market value for the completion of the acquisition, SofPulse® assets and Intellectual

  • GlobeNewswire

    Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan

    Los Angeles, CA, March 23, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a medical device company known for its innovative and effective pain management solutions -- announced today that it is entering the final stages of clearance to receive a Taiwan FDA (TFDA) License for Medical Devices to distribute its flagship product, SofPulse® in Taiwan. Sofpulse® medical devices are designed to accelerate recovery and reduce pain and edema post operatively. SofPulse® technology u

  • GlobeNewswire

    Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery

    Los Angeles, CA, March 15, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced details today of the remarkable experience of one of its Scientific Advisory Board Members, Dr. Gary Berns, while overseeing the rehabilitation treatments of Olympian and Surfing Champion Carlos Muñoz, following a devastating shoulder injury and subsequent accelerated recovery from highly invasive shoulder surgery utilizing Endonovo’s SofPulse® medical device. SofPulse® treatments applied to M

  • GlobeNewswire

    Endonovo Announces Distribution Agreement with Academy Medical

    Provide Improved Medical Services to VHA and U.S. Dept. of Defense Los Angeles, CA, March 06, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the signing of a Service-Disabled Veteran-Owned Small Business (SDVOSB) Government Reseller Agreement (Agreement or Contract) with Academy Medical, Inc. of West Palm Beach, FL to distribute SofPulse® medical devices to ensure its availability to the Veterans Health Administration (VHA) and Department of Defense (DoD) cont

  • GlobeNewswire

    Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg

    Los Angeles, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a medical device company specializing in pulsed electromagnetic field (PEMF) technology, announced today it will hold a question and answer session for shareholders on March 9, 2023 at 4:30pm EST with Ira Weisberg, President of Endonovo’s Medical Division. The meeting and dialogue with shareholders will be virtual and accessible through the following ZOOM link: https://us02web.zoom.us/j/86916857785?pwd=

  • GlobeNewswire

    Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off

    Los Angeles, CA, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the retention of Ocean Tomo, a part of J.S. Held, to conduct a fairness opinion analysis in connection with the proposed spin-off of Endonovo’s medical device assets to a newly formed Delaware company, SofPulse, Inc. Endonovo’s SofPulse® medical device offers patients and healthcare providers significant benefits including a viable treatment solution for post-surgical pain, edema and edem

  • GlobeNewswire

    Endonovo Partners with International Distributor for SofPulse® Line

    Partnership Expected to Increase SofPulse® Distribution and Revenues Los Angeles, CA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced a new non-exclusive stocking distributor agreement with Pulse Therapeutics Technology, Inc. (the “Distributor”) to purchase and distribute its SofPulse® medical devices into Mexico and Costa Rica. The Distributor, recognizing the treatment potential of the SofPulse® PEMF (Pulsed Electro Magnetic Frequency) device, recent

  • GlobeNewswire

    New Details on Endonovo’s Spin-Off of SofPulse, Inc.

    Los Angeles, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced today details regarding the planned spin-off of its medical device assets to a newly formed Delaware company, SofPulse, Inc. SofPulse, Inc. Will Operate Independently SofPulse, Inc. will operate independently from Endonovo and focus on developing commercialization initiatives for its SofPulse® medical device line. The spin-off will also include Endonovo's recently-announced telehealth initiativ

  • GlobeNewswire

    Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company

    Los Angeles, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) today announced details for its plan to spin off its current medical device division, known as NewCo, as a separate publicly-traded company. Endonovo’s other current division focuses on mergers and acquisitions (M&A) in the specialty construction sector and will seek to be uplisted to a national exchange. Spin-Off Produces Two Publicly-Traded Companies NewCo (the medical device division) will be run by Ir

  • GlobeNewswire

    Endonovo Targets Dept. of Defense, VA & Federal Contracts

    Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical device distribution through the U.S. Department of Defense (DoD), Veterans Administration (VA) and other federal healthcare facilities (FHS) contracts. President and Chief Commercial Officer of Endonovo’s Medical Division, Ira Weisberg, is overseeing the “Go to Market” strategy and is actively engaging

  • GlobeNewswire

    Endonovo Announces Advancement of International “Go to Market” Initiative

    Los Angeles, CA, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced an aggressive initiative to introduce and develop the sales and benefits of SofPulse® medical devices into multiple international markets as part of its global “Go to Market” strategy. President and Chief Commercial Officer of the Medical Division of Endonovo, Ira Weisberg, will be heading the efforts to expand the benefits of SofPulse® into international markets. With the announcement, W

  • GlobeNewswire

    Endonovo Announces Plans for Spin-off of Medical IP and Assets

    New Company To Be Formed for SofPulse® Medical Device Line Los Angeles, CA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to affect a spin-off of its medical device assets to a new company (“NewCo”) being formed by its current President and Chief Commercial Officer of its Medical Division, Ira Weisberg. Weisberg will be responsible for running NewCo independently from Endonovo and will develop commercialization initiatives through sales and mar

  • GlobeNewswire

    Endonovo Launches Telehealth Initiative

    Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options. The Endonovo Telehealth platform will provide alternative pain management options through its direct-to-consumer sales of prescription and non-prescript

  • GlobeNewswire

    Endonovo Names Ira Weisberg President to Guide Global Medical Expansion

    Los Angeles, CA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today named Ira Weisberg as President and Chief Commercial Officer of its Medical Division. “Ira will be responsible for expanding global sales and marketing operations, including: business development, acquisitions and fostering product innovation while overseeing advancement of SofPulse® and Roma® Pulsed Electro Magnetic Frequency (PEMF) medical devices distribution globally,” according to Chairman and

  • GlobeNewswire

    ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS

    Los Angeles, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced plans to explore strategic alternatives to maximize the shareholder value potential of its SofPulse® Pulsed Electro Magnetic Frequency (PEMF) proprietary assets. This may include, but is not limited to, discussions with investment bankers, equity fund managers, global medical technology consultants and other investment groups. “Endonovo’s management has created momentum for investment and

  • GlobeNewswire

    Endonovo Therapeutics Issues Corporate Update

    Highlights its previously-announced “Build Up Strategy” of acquiring complementary specialty service providers in the construction industry Los Angeles, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today issued an update regarding recent corporate developments. The Company noted advancement of its previously-announced “Build Up Strategy” of acquiring complementary specialty service providers in the construction industry. This corporate update is being provided

  • GlobeNewswire

    Endonovo Therapeutics Signs Definitive Asset Purchase Agreement to Acquire A Highly Profitable Texas Concrete Construction Company

    Los Angeles, CA., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) and Western Star Concrete LLC, a highly profitable Texas concrete construction company located in the greater Dallas region, today announced the signing of a definitive purchase agreement for Endonovo to acquire all of Western Star’s assets and business operations. The Agreement is a unique opportunity to greatly enhance Western Star’s position as a regional leader in the specialty concrete construction

  • GlobeNewswire

    Endonovo Therapeutics Releases Comparative Analysis Demonstrating

    More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and five published studies for SofPulse®. Product and technical

  • GlobeNewswire

    Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management

    Los Angeles, CA, July 21, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today released a comparative analysis detailing how its SofPulse® medical device out-performed all pharmaceutical competitors non-opioid alternatives for surgical pain management. Competitive post-operative pain management products compared and analyzed against Endonovo’s SofPulse® PEMF (Pulsed Electro-Magnetic Frequency) were: Pacira BioSciences, Inc. (PCRX) analgesic injectable Exparel®, Avanos Medical,

  • GlobeNewswire

    Endonovo Therapeutics Announces LOI to Acquire Specialty Construction Company

    Los Angeles, CA, June 09, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB:ENDV) today announced a Letter of Intent to purchase a highly-regarded market leading specialty concrete services company located in the Southern U.S. with unaudited 2021revenue of $47.7M and Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of $5.3M. Since 2018, growth for the target company has gone from $9.5 Million in revenue to over $47 Million in 2021 for an average CAGR of 106%. Once